Skip to main content

Xovoltib 50mg tablet| Afatinib Uses & Side effects

XOVOLTIB 50MG

DESCRIPTION

This is a Phase 2 trial examine the performance of a targeted cancer drug known as Xovoltib 50mg.
Xovoltib 50mg tablets prohibits the EGFR protein, which is accepting to be included in driving the growth of chordoma tumors.
This study is plan specifically for chordoma patients 18 years or older with recurrent or metastatic tumors.
Xovoltib 50mg which is used as prescription drugs under the guidance of oncologist physician.

INDICATION

Xovoltib 50mg tablets is used for the first-line treatment for patients with metastatic non-small cell lung cancer(NSCLC)

MECHANISM OF ACTION

Afatinib mechanism by preventing the activity of a group of proteins knowns as epidermal growth factor receptors (EGFR). Epidermal growth factor receptor is a protein which is included in the growth and spread of cancer cells; Afatinib works by inhibiting the action of this protein.
Afatinib should not be taken by people who having EGFR-negative tumors.

PRODUCT DETAILS

Brand : Xovoltib
Ingredients : Afatinib
Strength : 50mg
Manufactured : GSK pharmaceuticals
Package : 7 tablets in a strip
xovoltib 50mg

Xovoltib 50mg

PHARMACOKINETICS

• Time to peak plasma time is 2-5 hr and bioavailability are 92 %
• Human plasma protein bound is 95%
• The major circulating metabolites are covalent adducts to proteins.
• The drug excretion through feces is 85% and urine 4% • Half-life is 37 hr.

DOSAGE MANAGEMENT

For adult: 40mg taken once per day is the prescribed dose for adult patients with metastatic non-small cell lung cancer Age of 0-17 years prescribed dose is not being studied in children.
Avoid using of Xovoltib drug under 18 years of age
The prescribed dose for renal impairment is given 30mg taken once per day
Administration :
Administer the drug Xovoltib 50mg on an empty stomach.
Take the drug Xovoltib 50mg tablets 1 hour before or 2 hours after a meal
Avoid cutting or crushing the tablet
Overdosage : Overdose is reported in patients whom ingested 360mg of Xovoltib 50mg which causes in nausea, vomiting, asthenia, abdominal pain and hence provided supportive measurement for recovery.

PRECAUTIONS

Serious dehydration can occur with the use of Xovoltib 50mg tablets. This may be leads to serious or persistent diarrhea, vomiting, or reduced fluid intake. Dehydration can result in kidney failure, if it is severe enough. While on treatment with this medication, you may be encouraged to drink extra water.
During treatment with Xovoltib 50mg will result in hepatotoxicity; monitor with periodic liver testing; withhold or stoptreatment for serious or worsening liver tests
The drug may result in Interstitial lung disease (ILD)
when administrated to pregnant women, Xovoltib 50mg tablets will have foetus harm (embryo-fetal toxicity)
Discontinue the drug,if patients confirm with suspected keratitis or ulcerative keratitis
With Xovoltib 50mg have increased sunburn/phototoxicity; may aggravate rash or acne; patients use with caution to limit sun exposure and where sunscreen and protective clothing.
sometimes, Xovoltib 50mg tablets has been bind to corneal perforation, a serious injury to the part of the eye which focuses light into the eye. If you have any persistent eye pain or changes in vision, inform your doctor immediately.

lung cancer
LUNG CANCER

SIDE EFFECTS

Common side effects caused :
• Mild diarrhae for 1 day or less
• Decreased appetite
• Nausea and vomiting
• Mouth ulcer
• Acne, itching, dry skin
• Red colour, tenderness, swelling or other signs of infection around your fingernails or toenails
Serious side effects :
• Eye problems – blurred vision, watery eyes, increased sensitivity to light
• Liver problem – stomach pain, feeling tried, dark urine
• Heart problem
• Urine colour changes to dark
• Bleeding or bruising
• Weakness
• Blurred vision
• Rapid heartbeat
• Breathing trouble
• Cough and fever
• Yellowing the skins

DRUG INTERACTION

Co administration of Xovoltib 50mg with P-gp inhibitors (cyclosporine A, ketoconazole verapamil) will have high exposure to Afatinib
When interaction of Xovoltib 50mg tablets with P-gp inducers (carbamazepine, phenytoin, phenobarbital) will lowers the exposure to Afatinib

MISSED DOSE

If patient missed to take the dose of Xovoltib 50mg, then the missed dose must be skipped and follow the regular dosing schedule. Do not administer double the dose
Consult with doctor and follow the suggestions.

PREGNANCY

Pregnancy category: c
During treatment with Xovoltib 50mg tablets Pregnancy should avoid because the drug 
Xovoltib 50mg is administrated to a pregnant woman will harm the foetus.

LACTATION

Xovoltib 50mg tablets Excretion into human milk is unknown or will have adverse reaction in a child who is breastfed. Hence decision can take whether to stop breastfeeding or discontinuation of medicine.

STORAGE

• Xovoltib 50mg Store at 25°C
• Keep Xovoltib 50mg tablets away from children
• Protect away free from moisture and light.

CONTACT US 

EMAIL ID : millionhealthpharmaceuticals@gmail.com

PHONE NO : +91-9940472902
Labels:

Comments

Post a Comment

Popular posts from this blog

Xbira 250mg : Abiraterone acetate Cipla Uses, Side Effect, Price india

Drug profile of Xbira xbira 250mg tablet  are containing an active component known as Abiraterone acetate which exhibits anti-tumor activity against prostate cancer. xbira 250mg  Cipla is a derivative of androstene, which involves in the prohibition process of steroid 17 alpha hydroxylase and containing anti-neoplastic activity. Abiraterone acetate  xbira  is an oral tablet which is an active acetate ester form of steroidal compound known as Abiraterone with anti-androgenic activity. Abiraterone acetate  xbira 250mg tablet  is involved by interfering with testosterone activity by inhibiting the synthesis. PRODUCT DETAILS Brand name: Xbira Active substance: Abiraterone acetate Strength: 250mg Mfg: Cipla Pack: 120 tablets in a container Classified as: Anti-neoplastic agent Prescribing information of Xbira The most important indication of  xbira 250mg tablet   is; Metastatic castration resistance prostate cancer Metastatic high risk c...
Post a Comment
Read more

sovihep D

sovihep D Description The active substance is Sofosbuvir and Daclatasvir ( sovihep d tablet ), which is an inhibitor of the NS5A protein required for the synthesis of HCV. The main purpose of the  sovihep d  is antiviral therapy. It is active in the fight against viral hepatitis C (genotypes 1, 2, 3, 4). The essence of the impact is to block the development of HCV and its spread in the body of the carrier. HCV exists in different forms known as genotypes. Genotype 1 is the most common type of HCV genotype and  sovihep d tablet  is also the most difficult to treat using other treatments. Mechanism of Action: DCV is an HCV NS5A replication complex inhibitor. This NS5A  sovihep d  viral protein has enzymatic activity that is essential for HCV RNA replication and assembly. In replication it appears to play a role in the formation of a membranous web along with viral protein NS4B, and this web provides a platform for replication. The NS5A protein is compo...
Post a Comment
Read more

Erlonat 150 mg - Erlotinib Natco tablet Price, Cost India

Drug profile   erlonat    is a Natco pharma item which is containing a functioning substance known as Erlotinib, a first line medication of decision in metastatic phase of non little cell lung tumor. erlonat  150mg  is normally endorsed for the patients who are not counters to less than one chemotherapy regimen. erlonat  150mg tablet  is synthetically described as quinazoline subordinate, with hostile to neoplastic impact against tumor cells. erlonat   is pharmacologically arranged as tyrosine kinase inhibitor. erlonat  150mg    is altogether raising the serum aminotransferase levels amid the treatment and this may causes liver wounds. erlonat  150mg tablet    tablets are containing 150mg of Erlotinib as a hostile to tumor specialist. PRODUCT DETAILS Brand name:  Erlonat    Active constituent: Erlotinib Strength: 150MG Mfg: Natco pharma Pack: 30 tablets per container Catego...
Post a Comment
Read more